

**Editor**

Josef S Smolen

Associate Editors

Francis Berenbaum
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Kimme Hyrich
Rik Lories
Iain McInnes
Thomas Pap
David Pisetsky
Désirée van der Heijde
Kazuhiko Yamamoto

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 3655 5889
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)

Disclaimer: The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

Copyright: © 2022 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

ARD is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

Recommendation

- 601** The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS
K Cetin Gedik, L Lamot, M Romano, E Demirkaya, D Piskin, S Torreggiani, L A Adang, T Armangue, K Barchus, D R Cordova, Y J Crow, R C Dale, K L Durrant, D Eleftheriou, E M Fazzi, M Gattorno, F Gavazzi, E P Hanson, M A Lee-Kirsch, G A Montealegre Sanchez, B Neven, S Orcesi, S Ozen, M C Poli, E Schumacher, D Tonduti, K Uss, D Aletaha, B M Feldman, A Vanderver, P A Brogan, R Goldbach-Mansky

Viewpoint

- 614** Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors
M Säemann, A Kronbichler

Heroes and pillars of rheumatology

- 618** Marking the 50th anniversary of a seminal paper in rheumatology: did Baruj Benacerraf and Hugh McDevitt get it right?
J T Rosenbaum, T Gill, T M Martin, M Friedman, R Thompson

Rheumatoid arthritis

- 622** Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis
P Lopez-Romero, I de la Torre, E Haladyj, D Aletaha, J S Smolen

Systemic lupus erythematosus

- 632** Anti-RNP antibodies are associated with the interferon gene signature but not decreased complement levels in SLE
E L Hubbard, D S Pisetsky, P E Lipsky

Sjögren's syndrome

- 644** Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren's syndrome
M G A Broeren, J J Wang, G Balzaret, P J T A Groenen, B D C van Schaik, T Chataway, C Kaffa, S Bervoets, K M Hebeda, G Bounova, G J M Pruijn, T P Gordon, N De Vries, R M Thurlings

Vasculitis

- 653** Efficacy and safety of mavrilimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial
M C Cid, S H Unizony, D Blockmans, E Brouwer, L Dagna, B Dasgupta, B Hellmich, E Molloy, C Salvarani, B C Trapnell, K J Warrington, I Wicks, M Samant, T Zhou, L Pupim, J F Paolini, For the KPL-304-C004 Investigators

Paediatric rheumatology

- 662** Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA
Y Zhao, E Sullivan, M B Son, T Beukelman

Osteoarthritis

- 666** Osteoarthritis endotype discovery via clustering of biochemical marker data
F Angelini, P Widera, A Mobasheri, J Blair, A Struglics, M Uebelhoe, Y Henrotin, A CA Marijnissen, M Kloppenburg, F J Blanco, I K Haugen, F Berenbaum, C Ladel, J Larkin, A C Bay-Jensen, J Bacardit

- 676** Mechanical overloading promotes chondrocyte senescence and osteoarthritis development through downregulating FBXW7
H Zhang, Y Shao, Z Yao, L Liu, H Zhang, J Yin, H Xie, K Li, P Lai, H Zeng, G Xiao, C Zeng, D Cai, X Bai

Epidemiology

- 687** Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial
M Bonelli, D Mrake, S Tobudic, D Sieghart, M Koblichke, P Mandl, B Kornek, E Simader, H Radner, T Perkmann, H Haslacher, M Mayer, P Hofer, K Redlich, E Husar-Memmer, R Fritsch-Storck, R Thalhammer, K Stiasny, S Winkler, J S Smolen, J H Aberle, M Zeilinger, L X Heinz, D Aletaha

MORE CONTENTS ►



EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals open access scheme.

See <http://authors.bmj.com/open-access/>



Member since 2008

JMR0004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

- 695** Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry
P M Machado, S Lawson-Tovey, A Strangfeld, E F Mateus, K L Hyrich, L Gossec, L Carmona, A Rodrigues, B Raffener, C Duarte, E Hachulla, E Veillard, E Strakova, G R Burmester, G K Yardmci, J A Gomez-Puerta, J Zepa, L Kearsley-Fleet, L Trefond, M Cunha, M Mosca, M Cornalba, M Soubrier, N Roux, O Brocq, P Durez, R Conway, T Goulencok, J WJ Bijlsma, I B McInnes, X Mariette

- 710** Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
A C Medeiros-Ribeiro, K R Bonfiglioli, D S Domiciano, A Y Shimabuco, H C da Silva, C G S Saad, E F N Yuki, S G Pasoto, C S R Araujo, T L Nakai, C A Silva, T Pedrosa, L d V K Kupa, M S R Silva, G G M Balbi, E G Kallas, N E Aikawa, E Bonfa

- 720** Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases
J Hadjadj, D Planas, A Ouedrani, S Buffier, L Delage, Y Nguyen, T Bruel, M-C Stolzenberg, I Staropoli, N Ernak, L Macraigne, C Morbieu, S Henriquez, D Veyer, H Péré, M Casadevall, L Mouthon, F Rieux-Laucat, L Chatenoud, O Schwartz, B Terrier

- 729** Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study
D Mongin, K Lauper, A Finckh, T Frisell, D S Courvoisier

Letters

- 738** Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
M Teles, C M Connolly, S Frey, T P-Y Chiang, J J Alejo, B J Boyarsky, A A Shah, J Albayda, L Christopher-Stine, W A Werbel, D L Segev, J J Paik
- 740** Management of contemporary early undifferentiated arthritis: data on EULAR's recommendation on the risk of persistent disease
N K den Hollander, M Verstappen, T WJ Huizinga, A van der Helm-van Mil

- 741** Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies
M H Buch, W P Maksymowych, M Boers

- 742** Anti-RuvBL1/2 autoantibodies in patients with systemic sclerosis or idiopathic inflammatory myopathy and a nuclear speckled pattern
J-B Vulsteke, Y Piette, C Bonroy, P Verschueren, D Blockmans, S Vanderschueren, K G Claes, P De Haes, J L Lenaerts, W A Wuyts, T Matsushita, V Smith, E De Langhe, X Bossuyt

- 744** Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series
P Kvacskay, W Merkt, J Günther, N Blank, H-M Lorenz

Electronic pages

- e69** Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population
X M E Matthijssen, T W J Huizinga, A H M van der Helm-van Mil
- e70** Response to: 'Increasing incidence of autoantibody-negative RA is replicated and is partly explained by an aging population' by Matthijssen *et al*
E Myasoedova, J Davis, E L Matteson, C S Crowson
- e71** Comment on: 'Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population' by Kishikawa *et al*
K Kitamura, H Shionoya, K Terato, S Suzuki, R Fukai, S Uda, C Abe, H Takemori, K Nishimura, H Baba, T Waritani, K Katayama
- e72** Response to: 'Comment on 'Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population' by Kishikawa *et al.* by Kitamura *et al*
T Kishikawa, Y Maeda, T Nii, Y Okada
- e73** Neuroinflammatory events after anti-TNF α therapy
E Katsionoudis, E Pelechas, P V Voulgari, A A Drosos

- e74** Response to: 'Neuroinflammatory events after anti-TNF α therapy' by Kaltsonoudis *et al*
T I Kopp, B Delcoigne, E V Arkema, M Magyari, H Locht, F T Sellebjerg, R L Cordtz, D V Jensen, J Askeling, L Dreyer
- e75** Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus
C-Y Wu, M Tan, J-Y Huang, J-Y Chiou, J C-C Wei
- e76** Response to: 'Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus' by Wu *et al*
A Fanouriakis, G Bertias, D T Boumpas
- e77** Physician's global assessment is often useful in SLE, but not always: the case of clinical remission
M Zen, F Saccon, M Gatto, A Doria
- e78** Response to: 'Physician's global assessment is often useful in SLE, but not always: the case of clinical remission' by Zen *et al*
A Askanase, S Oon, M Huq, A Calderone, E F Morand, M Nikpour, C Aranow
- e79** Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?
E Chessa, M Piga, L Arnaud
- e80** Response to: 'Physician global assessment in systemic lupus erythematosus: can we rely on its reliability?' by Chessa *et al*
A Askanase, S Oon, M Huq, A Calderone, E F Morand, M Nikpour, C Aranow
- e81** Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopaenic purpura
W Xie, Z Zhang
- e82** Response to 'Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura' by Xie and Zhang
F-X Zhu, J-Y Huang, Q-Q, J C-C Wei
- e83** Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a need for a more accurate control group?
P Mertz, L Arnaud
- e84** Response to: 'Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a need for a more accurate control group?' by Mertz and Arnaud
F X Zhu, J-Y Huang, W Qingqing, J C C Wei
- e85** Associations of regular glucosamine use with all-cause and cause-specific mortality: causality assumptions need to be checked
S Safiri, M A Mansournia
- e86** Response to: 'Associations of regular glucosamine use with all-cause and cause-specific mortality: causality assumptions need to be checked' by Safiri and Mansournia
Z-H Li, Q-M Huang, C Mao
- e87** 'Finding the right one'
A A Zanwar
- e88** Response to: 'Finding the right one' by Zanwar
T Renson, F E Van den Bosch, D Elewaut